Biotech Stocks Newsletter – Wednesday February 7, 2018

0
718

Success for Allergan CGRP drug during phase 3 migraine trial

Co-primary endpoints were met when it came to a phase 3 trial of Allergan’s oral CGRP drug ubrogenpant. In the two hours after dosing, the drug provided much more relief than the placebo to intense migraine patients. On the other hand, the size of the effect, and the cases of increased liver enzymes leaves room for doubt about its forecast.

SEE FOR YOURSELF CLICK HERE!


Time To See A Biotech Rally?

One company has put together a leading management team, a strong pipeline of therapies, and holds a key biotechnology that could impact millions of people at risk. With the recent market pull-back, now could be an important time to be paying even closer attention to this emerging biotech company.

SEE FOR YOURSELF CLICK HERE!


AstraZeneca Focuses on $500M Buyout

Monotherapy development of a PD-1 drug has stopped according to AstraZeneca. The drug acquired a $500 million biotech buyout. There is a new focus of AstraZeneca’s takeover of Amplimmune, and this is MEDI0680.

SEE FOR YOURSELF CLICK HERE!

LEAVE A REPLY

Please enter your name here
Please enter your comment!